Literature DB >> 30080821

Chinese approval for Ascletis' HCV drug is first homegrown success.

Shannon Ellis.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30080821     DOI: 10.1038/nbt0818-675a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Hong Kong stock exchange opens to biotechs.

Authors:  Shannon Ellis
Journal:  Nat Biotechnol       Date:  2018-06-06       Impact factor: 54.908

  1 in total
  1 in total

Review 1.  Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.

Authors:  Miao Miao; Xixi Jing; Erik De Clercq; Guangdi Li
Journal:  Drug Des Devel Ther       Date:  2020-07-14       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.